CN Patent

CN113501871B — 一种固液相结合制备达西高血糖素的方法

Assigned to Sinopeptide Biomedical Group Co ltd · Expires 2022-10-28 · 4y expired

What this patent protects

本发明公开了一种固液相结合制备达西高血糖素的方法，本发明首次采用液相法合成单体Boc‑His(Trt)‑Ser(tBu)‑Gln(Trt)‑OH、Fmoc‑Gly‑Thr(tBu)‑OH、Fmoc‑Leu‑Asp(OtBu)‑OH、Fmoc‑Ala‑Arg(Pbf)‑OH、Fmoc‑Ala‑Glu(OtBu)‑OH、Fmoc‑Val‑Lys(Boc)‑OH、Fmoc‑Leu‑Glu(OtBu)‑OH，然后再用上述单体作原料固相制备达西高血糖素。本发明能够有效的提高粗肽的纯度，降低纯化的难度，提高终产品的收率，有利于合成规模的大规模工业化应用，降低生产成本…

USPTO Abstract

本发明公开了一种固液相结合制备达西高血糖素的方法，本发明首次采用液相法合成单体Boc‑His(Trt)‑Ser(tBu)‑Gln(Trt)‑OH、Fmoc‑Gly‑Thr(tBu)‑OH、Fmoc‑Leu‑Asp(OtBu)‑OH、Fmoc‑Ala‑Arg(Pbf)‑OH、Fmoc‑Ala‑Glu(OtBu)‑OH、Fmoc‑Val‑Lys(Boc)‑OH、Fmoc‑Leu‑Glu(OtBu)‑OH，然后再用上述单体作原料固相制备达西高血糖素。本发明能够有效的提高粗肽的纯度，降低纯化的难度，提高终产品的收率，有利于合成规模的大规模工业化应用，降低生产成本。

Drugs covered by this patent

dasiglucagon-hydrochloride (DASIGLUCAGON HYDROCHLORIDE)

Patent Metadata

Patent number: CN113501871B
Jurisdiction: CN
Classification: —
Expires: 2022-10-28
Drug substance claim: No
Drug product claim: No
Assignee: Sinopeptide Biomedical Group Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.